Rybrevant Disease Interactions

Amivantamab can cause interstitial lung disease (ILD)/pneumonitis. Care should be exercised when using this drug in patients with preexisting pulmonary impairment. Amivantamab should be immediately withheld in patients with suspected ILD/pneumonitis and permanently discontinued if ILD/pneumonitis is confirmed. Patients should be monitored for new/worsening symptoms indicative of ILD/pneumonitis.

Care should be exercised when using amivantamab in patients with moderate (total bilirubin 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN]) to severe (total bilirubin greater than 3 x ULN) liver dysfunction as the pharmacokinetics of amivantamab have not been studied in these patients. No clinically significant differences in the pharmacokinetics of amivantamab were observed based on mild liver dysfunction (total bilirubin up to ULN and AST greater than ULN or total bilirubin greater than ULN and up to 1.5 x ULN).

Care should be exercised when using amivantamab in patients with severe renal dysfunction (CrCl 15 to 29 mL/min) or end-stage renal disease (CrCl less than 15 mL/min) as the pharmacokinetics of amivantamab have not been studied in these patients. No clinically significant differences in the pharmacokinetics of amivantamab were observed based on CrCl 29 to 276 mL/min.